Development of c-MET pathway inhibitors

Expert Opinion on Investigational Drugs

Volumn 20, Issue 9, 2011, Pages 1225-1241

  Liu, Xiangdong ^a   Newton, Robert C ^a   Scherle, Peggy A ^a  

^a Experimental Station   (United States)

Author keywords

C MET; Cancer; Hepatocyte growth factor; Inhibitor; Receptor tyrosine kinase

Indexed keywords

AMG 208; AMG 337; AMUVATINIB; AV 299; BMS 777607; CELL CYCLE PROTEIN 37; CRIZOTINIB; E 7050; ERLOTINIB; FORETINIB; HEAT SHOCK PROTEIN 90; INCB 28060; JNJ 38877605; MGCD 265; MK 2461; ONARTUZUMAB; ONCOPROTEIN; PRO 143933; PROTEIN C MESENCHYMAL EPITHELIA TRANSITION FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; RILOTUMUMAB; SCATTER FACTOR; SUNITINIB; TIVANTINIB; UNCLASSIFIED DRUG; XL 184;

ANGIOGENESIS; CANCER PATIENT; CANCER THERAPY; CARCINOGENESIS; COMBINATION CHEMOTHERAPY; DERMATITIS; DIARRHEA; DRUG DEVELOPMENT; DYSPNEA; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; INFECTION; INTERSTITIAL LUNG DISEASE; KIDNEY CANCER; LUNG CANCER; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; METASTASIS; MUTATION; NAUSEA; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RASH; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; STOMACH CANCER; THYROID CANCER; TOXICITY; TUMOR GROWTH; UPREGULATION; VOMITING;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; HEPATOCYTE GROWTH FACTOR; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; NEOPLASM METASTASIS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 80051760389     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.600687     Document Type: Review

References (148)

1. Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25 (Pubitemid 37493640)
2. Christensen JG, Burrows J, Salgia R. c-MET as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005;225:1-26 (Pubitemid 40732764)
3. Liu X, Yao W, Newton RC, et al. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs 2008;17:997-1011
4. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504-16 (Pubitemid 351767118)
5. Cooper CS, Park M, Blair DG, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984;311:29-33 • Description of the original cloning of c-MET gene. (Pubitemid 14065275)
6. Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989;342:440-3 (Pubitemid 19277521)
7. Stoker M, Gherardi E, Perryman M, et al. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 1987;327:239-42 (Pubitemid 17071053)
8. Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 1984;122:1450-9 (Pubitemid 14073577)
9. Russell WE, McGowan JA, Bucher NL. Partial characterization of a hepatocyte growth factor from rat platelets. J Cell Physiol 1984;119:183-92 (Pubitemid 14112405)
10. Schmidt C, Bladt F, Goedecke S, et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995;373:699-702
11. Bladt F, Riethmacher D, Isenmann S, et al. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995;376:768-71
12. Uehara Y, Minowa O, Mori C, et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 1995;373:702-5
13. Di Renzo MF, Narsimhan RP, Olivero M, et al. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 1991;6:1997-2003 (Pubitemid 21924039)
14. Roos F, Ryan AM, Chamow SM, et al. Induction of liver growth in normal mice by infusion of hepatocyte growth factor/scatter factor. Am J Physiol 1995;268(2 Pt 1):G380-6
15. Giebeler A, Boekschoten MV, Klein C, et al. c-Met confers protection against chronic liver tissue damage and fibrosis progression after bile duct ligation in mice. Gastroenterology 2009;137:297-308
16. Nakamura T, Mizuno S, Matsumoto K et al. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 2000;106:1511-19 (Pubitemid 32038589)
17. Rabkin R, Fervenza F, Tsao T, et al. Hepatocyte growth factor receptor in acute tubular necrosis. J Am Soc Nephrol 2001;12:531-40 (Pubitemid 32180022)
18. Ponzetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994;77:261-71 (Pubitemid 24138623)
19. Weidner KM, Di Cesare S, Sachs M, et al. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelia morphogenesis. Nature 1996;384:173-6 (Pubitemid 26386473)
20. Schaeper U, Gehring NH, Fuchs KP, et al. Coupling of Gab1 to c-Met, Grb2 and Shp2 mediates biological responses J Cell Biol 2000;149:1419-32 (Pubitemid 30437616)
21. Royal I, Fournier TM, Park M. Differential requirement of Grb2 and PI3-kinase in HGF/SF-induced cell motility and tubulogenesis. J Cell Physiol 1997;173:196-201 (Pubitemid 27481129)
22. Xiao GH, Jeffers M, Bellacosa A, et al. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci USA 2001;98:247-52 (Pubitemid 32095895)
23. Gual P, Giordano S, Williams TA, et al. Sustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesis. Oncogene 2000;19:1509-18 (Pubitemid 30175672)
24. Trusolino L, Bertotti A, Comoglio PM. A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell 2001;107:643-54 (Pubitemid 34014865)
25. Guo A, Villen J, Kornhauser J, et al. Signaling networks assembled by oncogenic EGFR and c-MET. Proc Natl Acad Sci USA 2008;105:692-7 (Pubitemid 351171770)
26. Bonine-Summers AR, Aakre ME, Brown KA, et al. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biol Ther 2007;6:561-70 (Pubitemid 47328331)
27. Khoury H, Naujokas MA, Zuo D, et al. HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol Biol Cell 2005;16:550-61 (Pubitemid 40165554)
28. Hepatocyte growth factor/scatter factor, Met and cancer references. Available from: http://www.vai.org/met/•. A summary of experimental evidence for the involvements of HGF and c-MET in a variety of human cancers with web links to related references.
29. Ma J, Defrances MC, Zou C, et al. Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer. J Clin Invest 2009;119:478-91
30. Wang P, Nishitani MA, Tanimoto S, et al. Bladder cancer cell invasion is enhanced by cross-talk with fibroblasts through hepatocyte growth factor. Urology 2007;69:780-4 (Pubitemid 46574944)
31. Moriyama T, Kataoka H, Koono M, et al. Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors. Int J Mol Med 1999;3:531-6
32. Abounader R, Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol 2005;7:436-51 (Pubitemid 41555616)
33. Yamashita J, Ogawa M, Yamashita S, et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 1994;54:1630-3 (Pubitemid 24116158)
34. Walker F, Kermorgant S, Darai E, et al. Hepatocyte growth factor and c-Met in cervical intraepithelial neoplasia: overexpression of proteins associated with oncogenic human papillomavirus and human immunodeficiency virus. Clin Cancer Res 2003;9:273-884
35. Kammula US, Kuntz EJ, Francone TD, et al. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett 2007;219-28 (Pubitemid 46330555)
36. Wu CW, Li AF, Chi CW, et al. Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma. 1998;5:817-22
37. Uchida D, Kawamata H, Omotehara F, et al. Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance. Int J Cancer 2001;93:489-96 (Pubitemid 32701407)
38. Betsunoh H, Mukai S, Akiyama Y, et al. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. Cancer Sci 2007;98:491-8 (Pubitemid 46562738)
39. Daveau M, Scotte M, Francois A, et al. Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol Carcinog 2003;36:13-41
40. Nakamura Y, Niki T, Goto A, et al. c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci 2007;98:1006-13 (Pubitemid 46865384)
41. Topcu-Yilmaz P, Kiratli H, Saglam A, et al. Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma. Melanoma Res 2010;20:126-32
42. Harvey P, Warn A, Newman P, et al. Immunoreactivity for hepatocyte growth factor/scatter factor and its receptor, met, in human lung carcinomas and malignant mesotheliomas. J Pathol 1996;180:389-94 (Pubitemid 27014076)
43. Fukuda T, Ichimura E, Shinozaki T, et al. Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. Pathol Int 1998;48:757-62 (Pubitemid 28455692)
44. Baykal C, Demirtas E, Al A, et al. Comparison of hepatocyte growth factor levels of epithelial ovarian cancer cyst fluids with benign ovarian cysts. Int J Gynecol Cancer 2004;14:152-6 (Pubitemid 38280638)
45. Ide T, Kitajima Y, Miyoshi A, et al. The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling. Ann Surg Oncol 2007;14:2600-7 (Pubitemid 47389573)
46. Humphrey PA, Halabi S, Picus J, et al. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 150005/9480. Clin Genitourin Cancer 2006;4:269-74 (Pubitemid 43779884)
47. Papotti M, Olivero M, Volante M, et al. Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid. Endocr Pathol 2000;11:19-30 (Pubitemid 30307941)
48. Verstovsek S, Kantarjian H, Estey E, et al. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia 2001;15:1165-70 (Pubitemid 32776439)
49. Onimaru Y, Tsukasaki K, Murata K, et al. Autocrine and/or paracrine growth of aggressive ATLL cells caused by HGF and c-Met. Int J Oncol 2008;33:697-703
50. Zhelyazkova AG, Tonchev AB, Kolova P, et al. Prognostic significance of hepatocyte growth factor and microvessel bone marrow density in patients with chronic myeloid leukaemia. Scand J Clin Lab Invest 2008;68:492-500
51. Etto L, Lacerda E, Baiocchi O, et al. Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma. Leuk Lymphoma 2008;49:257-64 (Pubitemid 351193917)
52. Seidel C, Borset M, Hjorth-Hansen H, et al. Role of hepatocyte growth factor and its receptor c-met in multiple myeloma. Med Oncol 1998;15:145-53 (Pubitemid 28496882)
53. Wullich B, Muller HW, Fischer U, et al. Amplified met gene linked to double minutes in human glioblastoma. Eur J Cancer 1993;29A:1991-5 (Pubitemid 23324360)
54. Fischer U, Muller HW, Sattler HP, et al. Amplification of the MET gene in glioma. Genes Chromosomes Cancer 1995;12:63-5
55. Di Renzo MF, Olivero M, Giacomini A, et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1995;1:147-54
56. Zeng ZS, Weiser MR, Kuntz E, et al. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett 2008;265:258-69
57. Nakajima M, Sawada H, Yamada Y, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999;85:1894-902 (Pubitemid 29202761)
58. Kuniyasu H, Yasui W, Kitadai Y, et al. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 1992;189:227-32 (Pubitemid 23030031)
59. Tong CY, Hui AB, Yin XL, et al. Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization. J Neurosurg 2004;100(2 Suppl):187-93 (Pubitemid 38141346)
60. Toschi L, Cappuzzo F. Clinical implications of MET gene copy number in lung cancer. Future Oncol 2010;6:239-47
61. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43 • The first report showing that c-MET amplification exists in gefitinib (a small molecule EGFR kinase inhibitor) resistant lung cancer patients, implicating that c-MET amplification may confer resistance to other targeted therapies like EGFR inhibitors. (Pubitemid 46799492)
62. Houldsworth J, Cordon-Cardo C, Ladanyi M, et al. Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res 1990;50:6417-22 (Pubitemid 20323708)
63. Moon YM, Weil RJ, Pack SD, et al. Missense mutation of the MET gene detected in human glioma. Mod Pathol 2000;13:973-7
64. Finegold DN, Schacht V, Kimak MA, et al. HGF and MET mutations in primary and secondary lymphedema. Lymphat Res Biol 2008;6:65-8 (Pubitemid 351873446)
65. Lee JH, Han SU, CHO H, et al. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 2000;19:4847-53
66. Di Renzo MF, Olivero M, Martone T, et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000;19:1547-55 (Pubitemid 30175676)
67. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73 (Pubitemid 27198158)
68. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999;18:2343-50 (Pubitemid 29192711)
69. Park WS, Dong SM, Kim SY, et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 1999;59:307-10 (Pubitemid 29048858)
70. Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003;63:6272-81 (Pubitemid 37255174)
71. Kong-Beltran M, Seshagiri S, Zha J, et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 2006;66:283-9 (Pubitemid 43166034)
72. Jagadeeswaran R, Ma PC, Seiwert TY, et al. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 2006;66:352-61 (Pubitemid 43166042)
73. Tanyi J, Tory K, Rigo J, et al. Evaluation of the tyrosine kinase domain of the Met proto-oncogene in sporadic ovarian carcinomas. Pathol Oncol Res 1999;5:187-91 (Pubitemid 29510771)
74. Wasenius VM, Hemmer S, Karjalainen-Lindsberg ML, et al. MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma. Am J Surg Pathol 2005;29:544-9 (Pubitemid 40411189)
75. Miyata Y, Sagara Y, Kanda S, et al. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and-7 and E-cadherin. Hum Pathol 2009;40:496-504
76. Kong DS, Song SY, Kim DH, et al. Prognostic significance of c-MET expression in glioblastomas. Cancer 2009;115:140-8
77. Camp RL, Rimm EB, Rimm DL. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 1999;86:2259-65 (Pubitemid 30010366)
78. Baykal C, Ayhan A, Al A, et al. Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomas. Gynecol Oncol 2003;88:123-9 (Pubitemid 36263369)
79. Aishima SI, Taguchi K, Sugimachi K, et al. c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology 2002;40:269-78 (Pubitemid 34227118)
80. Lo Muzio L, Farina A, Coccia E, et al. Effect of c-Met expression on survival in head and neck squamous cell carcinoma. Tumour Biol 2006;27:115-21
81. Ueki T, Fujimoto J, Suzuki T, et al. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology 1997;25:619-23 (Pubitemid 27106443)
82. Ichumura E, Maeshima A, Nakajima T, et al. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 1996;87:1063-9 (Pubitemid 26392044)
83. Patane S, Avnet S, Coltella N, et al. MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res 2006;66:4750-7
84. Sawada K, Radjabi AR, Shinomiya N, et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007;67:1670-9 (Pubitemid 46383393)
85. Pisters LL, Troncoso P, Zhau HE, et al. c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 1995;154:293-8
86. Tjin EP, Groen RW, Vogelzang I, et al. Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood 2006;107:760-8 (Pubitemid 43076403)
87. Graveel C, Su Y, Koeman J, et al. Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci USA 2004;101:17198-203 (Pubitemid 39627797)
88. Ponzo MG, Lesurf R, Petkiewicz S, et al. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci USA 2009;106:12903-8
89. Ma Y, Yuan RQ, Fan S, et al. Identification of genes that modulate sensitivity of U373MG glioblastoma cells to cis-platinum. Anticancer Drugs 2006;17:733-51 (Pubitemid 44310171)
90. Akervall J, Guo X, Qian CN, et al. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients. Clin Cancer Res 2004;10:8204-13 (Pubitemid 40053379)
91. Lal B, Xia S, Abounader R, Laterra J. Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. Clin Cancer Res 2005;11:4479-86 (Pubitemid 40825638)
92. Agarwal S, Zerillo C, Kolmakova J, et al. Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells. Br J Cancer 2009;100:941-9
93. Eder JP, Vande Woude GF, Boerner SA, et al. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009;15:2207-14
94. Munshi N, Jeay S, Li Y, et al. ARQ197, a novel and selective inhibitor of the human c-Met receptor tyrsoine kinase with antitumor activity. Mol Cancer Ther 2010;9:1544-53
95. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-MET, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67:4408-17 • A paper detailing preclinical properties of PF2341066 and first time disclosure of the structure of a c-MET inhibitor being investigated in the clinic. (Pubitemid 46815090)
96. Timofeevski SL, McTigue MA, Ryan K, et al. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinase studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry 2009;48:5339-49
97. Perera T, Lavrijssen T, Janssens B, et al. JNJ-38877605: a selective Met kinase inhibitor inducing regression of Met-driven tumor models [abstract 4837]. The AACR Annual Meeting; 2008
98. Buchanan SG, Hendle J, Lee PS, et al. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol Cancer Ther 2009;8:3181-90
99. Schroeder GM, An Y, Cai ZW, et al. Discovery of N-(4-(2-amino-3- chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1, 2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. J Med Chem 2009;52:1251-4
100. Liu L, Greger J, Shi H, et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 2009;69:6871-8
101. Pan BS, Chan GK, Chenard M, et al. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res 2010;70:1524-33
102. Nakagawa T, Tohyama O, Yanaguchi A, et al. E7050: a dual c-MET and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci 2010;101:210-15
103. Merchant M, Zheng Z, Romero MS, et al. One-armed 5D5 (OA5D5) is a potent humanized HGF-blocking anti-c-Met monovalent antibody that inhibits HGF-dependent activity in vitro and demonstrated anti-tumor efficacy in vivo [abstarct LB-372]. The AACR Annual Meeting; 2007
104. Giordano S. Rilotumumab, a mAb against human hepatocyte growth factor for the treatment of cancer. Curr Opin Mol Ther 2009;11:448-55
105. Available from: http/clinicaltrials.gov/
106. Mekhail T, Rich T, Rosen L, et al. Fina results: a dose escalation phase I study of ARQ197, a selective c-Met inhibitor, in patients with metastatic solid tumors [abstract 3548]. J Clin Oncol 2009;27:15s
107. Schiller JH, Akerley WL, Brugger W, et al. Results from ARQ 197-209: a global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) [abstract LBA7502]. J Clin Oncol 2010;28:359s
108. Yap TA, Olmos D, Brunetto AT, et al. Phase I trial of a selective c-MET inhibitor ARQ197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 2011;29:1271-9
109. Liu X, Koblish H, Wang Q, et al. Discovery and characterization of INCB028060, a novel, potent and selective Met RTK inhibitor for cancer treatment [abstract 2577]. The AACR Annual Meeting; 2008
110. Schadt O, Dorsch D, Stieber F, et al. Preclinical characterization of EMD 1214063 - a selective c-Met kinase inhibitor in clinical phase 1 [abstract 216]. The EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; 2010
111. Bladt F, Blaukat A, Dorsch D, et al. Identification and preclinical characterization of EMD1204831 - a selective c-Met kinase inhibitor in clinical phase I [abstract 2786]. The AACR Annual Meeting; 2011
112. Kwak EL, Camidge DR, Clark J, et al. Clinical activity observed in a phase I dose escalation trial of an oral c-Met and ALK inhibitor, PF-02341066 [abstract 3509]. J Clin Oncol 2009;27:15s
113. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703
114. Kurzrock R, Sherman S, Hong D, et al. A phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC) [abstract 379]. The AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics, Discovery, Biology, and Clinical Applications; 2008
115. Schoffski P, Sgroi M, Burris HA, et al. Phase 2 randomized discontinuation trial (RDT) of XL184 in patients (pts) with advanced solid tumors [abstract 371]. The AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics; 2010
116. Smith DC, Smith MR, Small EJ, et al. Phase 2 study of cabozantinib (XL184) in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease [abstract 127]. The ASCO Genitourinary Cancer Symposium; 2011
117. Eder JP, Heath E, Appleman L, et al. Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors [abstract 3526]. J Clin Oncol 2007;25:18s
118. Shapiro GI, Heath E, Malburg L, et al. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL880, a VEGFR and MET kinase inhibitor, administrated daily to patients with advanced malignancies [abstract B248]. The 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2007
119. Srinivasan R, Linehan WM, Vaishampayan U, et al. A phase II study of two dosing regimens of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillary renal carcinoma (PRC) [abstract 5103]. J Clin Oncol 2009;27:15s
120. Beaulieu N, Beaulieu C, Dupont I, et al. Preclinical development of MGCD265, a potent orally active c-Met/VEGFR multi-target kinase inhibitor [abstract 4838]. The AACR Annual Meeting; 2008
121. Health EI, LoRusso P, Kurzrock R, et al. A phase I study of oral administration of MGCD265 in patients with advanced malignancies (Study 265-102) [abstract 3108]. The ASCO Annual Meeting; 2010
122. Zhang Y, Kaplan-Lefko PJ, Rex K, et al. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo. Cancer Res 2008;68:6680-7
123. Tolcher AW, Mita M, Rosen L, et al. Clinical responses to MP-470, an oral RAD51 inhibitor, in combination with standard of care doublet chemotherapy, in patients with SCLC and NE malignancies: a phase 1 case series [abstract 7936]. The IASLC 13th World Conference on Lung Cancer; 2009
124. Camacho LH, Moulder SL, LoRusso PM, et al. First in human phase I study of MK-2461, a small molecule inhibitor of c-Met, for patients with advanced solid tumors. J Clin Oncol 2008;26s: abstract 14657
125. Moss RA, Bothos JG, Patel PH, et al. Final results from the Phase I study of MetMab, a monovalent antagonist antibody to the receptor Met, dosed as single agent and in combination with bevacizumab in patients with advanced solid tumors [abstract 4717]. The AACR Annual Meeting; 2011
126. Spigel D, Ervin T, Ramlau R, et al. Randomized multicenter double-blind placebo-controlled phase II study evaluating MetMAb, an antibody to Met receptor, in combination with erlotinib, in patients with advanced non-small-cell lung cancer [abstract LBA15]. The 35th Congress of the European Society for Medical Oncology; 2010 •• A report of the first randomized double-blind placebo-controlled clinical trial of a c-MET pathway specific anti-c-MET antibody showing significant clinical benefit exclusively in NSCLC patients whose tumors had high levels of c-MET expression.
127. Gordon MS, Mendelson DS, Sweeney C, et al. Interim results from a first-in-human study with AMG102, a full human monoclonal antibody that neutralizes hepatocyte growth factor (HGF), the ligand to c-Met receptor, in patients (pts) with advanced solid tumors [abstract 3551]. The ASCO Annual Meeting; 2007 • A report describing Phase I safety data and early evidence of clinical activity of antagonistic anti-HGF mAb AMG102.
128. Sequist L, Akerley WL, Brugger W, et al. Final results from ARQ 197-209: a global randomized placebo-controlled phase 2 clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR-inhibitor native patients with advanced non-small cell lung cancer (NSCLC) [abstract 3630]. The 35th Congress of the European Society for Medical Oncology; 2010
129. Zhuang Z, Park WS, Pack S, et al. Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet 1998;20:66-9 • A genetic analysis identifying a non-random duplication of the chromosome bearing c-MET mutations in hereditary papillary renal carcinomas and implicating this event in tumorigenesis. (Pubitemid 28410347)
130. Mineo R, Costantino A, Frasca F, et al. Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels. Endocrinology 2004;145:4355-65 (Pubitemid 39120585)
131. Di Renzo MF, Olivero M, Ferro S, et al. Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene 1992;7:2549-53
132. Chattopadhyay C, El-Naggar AK, Williams MD, et al. Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma. Head Neck 2008;30:991-1000
133. Sherman SI. Molecularly targeted therapies for thyroid cancers. Endocr Pract 2009;15:605-11
134. De Groot JW, Links TP, Plukker JT, et al. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 2006;27:535-60 (Pubitemid 44213230)
135. Hurle RA, Davies G, Parr C, et al. Hepatocyte growth factor/scatter factor and prostate cancer: a review. Histol Histopathol 2005;20:1339-49 (Pubitemid 41489177)
136. Fukuda T, Ichimura E, Shinozaki T, et al. Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. Pathol Int 1998;48:757-62 (Pubitemid 28455692)
137. Rong S, Segal S, Anver M, et al. Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci USA 1994;91:4731-5 (Pubitemid 24177723)
138. Jeffers M, Rong S, Woude GF. Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J Mol Med 1996;74:505-13 (Pubitemid 26306792)
139. Uchida D, Kawamata H, Omotehara F, et al. Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance. Int J Cancer 2001;93:489-96 (Pubitemid 32701407)
140. Jeffers M, Fiscella M, Webb CP, et al. The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci USA 1998;95:14417-22 (Pubitemid 28549382)
141. Davies G, Watkins G, Mason MD, et al. Targeting the HGF/SF receptor c-met using a hammerhead ribozyme transgene reduces in vitro invasion and migration in prostate cancer cells. Prostate 2004;60:317-24 (Pubitemid 39050651)
142. Tomioka D, Maehara N, Kuba K, et al. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res 2001;61:7518-24 (Pubitemid 32995042)
143. Jun. HT, Sun J, Rex K, et al. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res 2007;13:6735-42 (Pubitemid 350206811)
144. Merchant M, Zhang YM, Su Y, et al. MetMAb significantly enhances anti-tumor activity of anti-VEGF and/or erlotinib in several animal tumor models [abstract 556]. The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2008
145. Janne PA, Wax M, Leach J, et al. Targeting MET with XL184 to reverse EGFR tyrosine kinase inhibitor (TKI) resistance in NSCLC: impact of preclinical studies on clinical trial design. Eur J Cancer 2008;6:abstract 552
146. Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81
147. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1018-29 (Pubitemid 47629897)
148. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26